Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
J Hepatol. 2022 Apr;76(4):800-811. doi: 10.1016/j.jhep.2021.12.004. Epub 2021 Dec 13.
J Hepatol. 2022.
PMID: 34915054
Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice.
van den Hoek AM, Pieterman EJ, van der Hoorn JW, Iruarrizaga-Lejarreta M, Alonso C, Verschuren L, Skjæret T, Princen HMG, Fraser DA.
van den Hoek AM, et al. Among authors: skjaeret t.
Hepatol Commun. 2019 Dec 24;4(2):193-207. doi: 10.1002/hep4.1453. eCollection 2020 Feb.
Hepatol Commun. 2019.
PMID: 32025605
Free PMC article.
Item in Clipboard
Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative.
Stokman G, van den Hoek AM, Denker Thorbekk D, Pieterman EJ, Skovgård Veidal S, Basta B, Iruarrizaga-Lejarreta M, van der Hoorn JW, Verschuren L, Berbée JFP, Rensen PCN, Skjaeret T, Alonso C, Feigh M, Kastelein JJP, Friedman SL, Princen HMG, Fraser DA.
Stokman G, et al. Among authors: skjaeret t.
Liver Int. 2020 Nov;40(11):2860-2876. doi: 10.1111/liv.14643.
Liver Int. 2020.
PMID: 32841505
Free PMC article.
Item in Clipboard
Cite
Cite